Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

BrightSpring Health Services (BTSG) Gains from Sales and Divestitures (2024 - 2025)

BrightSpring Health Services filings provide 2 years of Gains from Sales and Divestitures readings, the most recent being $1.9 million for Q4 2025.

On a quarterly basis, Gains from Sales and Divestitures rose 705.18% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 705.18% increase, with the full-year FY2025 number at $1.9 million, up 705.18% from a year prior.
Gains from Sales and Divestitures hit $1.9 million in Q4 2025 for BrightSpring Health Services, up from $241971.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $1.9 million in Q4 2025 to a low of $241971.0 in Q4 2024.